The briefing provides an at-glance-view of some of the big things happening in the information universe surrounding COVID-19. The views presented here are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.

Download this Scan

ECRI Horizon Scanning has selected the topics below as those with potential for impact relative to COVID-19 in the United States within the next 12 months. All views presented are preliminary and based on readily available information at the time of writing.

Because these topics are rapidly developing, we cannot guarantee the accuracy of this information after the date listed on this publication. In addition, all views expressed in the commentary section are solely those of ECRI Horizon Scanning and have not been vetted by other stakeholders.

Anakinra (Kineret) for Treating COVID-19 with Acute Respiratory Distress Syndrome and Hyperinflammation

At a Glance

  • Anakinra is a commercially available interleukin-1 (IL-1) receptor antagonist that might provide a treatment option for acute respiratory distress syndrome (ARS).
  • Ninety percent of patients with moderate-to-severe ARS given high-dose anakinra and standard of care (SoC) survived at day 21 compared with 56% given SoC alone in a small, retrospective study.
  • Anakinra was given intravenously at a dose of 5 mg/kg twice daily for 9 days on average, costing between about $1320 and $1580 daily with the current formulation.

COVID-19 Self-Collection Test Kit

At a Glance

  • The COVID-19 self-collection test kit permits at-home collection of a nasal sample appropriate for SARS-CoV-2 PCR-based diagnostic testing for people who have disease symptoms or have had possible exposure to the virus.
  • The test kit might reduce viral transmission by eliminating the need for health care providers to collect nasal specimens.
  • FDA granted the COVID-19 self-collection test kit Emergency Use Authorization in April 2020. It costs $119 (patient assistance is available).

We welcome your comments on this Scan. Send them by email to [email protected] or
by mail to: Patient-Centered Outcomes Research Institute, 1828 L Street, NW, Suite 900, Washington, DC 20036.

Commentary in this COVID-19 Scan reflects preliminary views of ECRI Horizon Scanning and internal ECRI stakeholders. This information contained in this document has not been vetted by other stakeholders.


Posted: June 9, 2020

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails highlighting results of our funded studies, newly funded research and engagement awards, opportunities to apply for funding, stakeholder workshops, and original feature stories about our funded projects.

Sign Up for Updates

Image

Hand pointing to email icon